Related Compounds
Non-peptide or next-generation compounds frequently discussed alongside peptides including GLP-1 agonists, dual/triple agonists, and metabolic agents.
3 peptides in this category
5-Amino-1MQ
5-Amino-1MQ is a small-molecule methylquinolinium derivative that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that ...
Preclinical only (cell culture and mouse models). Growing clinical interest. NoRetatrutide
Retatrutide is an investigational first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, it has demo...
Phase III trials ongoing (7 additional Phase III readouts expected in 2026). NotSurvodutide
Survodutide (BI 456906) is an investigational dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed by Boehringer Ingelheim. Unlike ...
Phase II trials completed for obesity and NASH (2023-2024). Phase III trials ini